Streetbeat News

Earnings

GRTX

Galera Therapeutics reported Q2 losses of $(0.48) per share, missing the analyst consensus estimate of $(0.44) by 9.09%. This is an 11.11% increase over losses from the same period last year. The company's cash and equivalents, including short-term investments, were pegged at $38.76M at the end of the quarter.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:27 am

ZURA

Zura Bio (NASDAQ:ZURA) reported Q2 losses of $(1.31) per share, missing the analyst consensus estimate of $(0.25) by 424 percent. However, this is an 86.27 percent increase over losses of $(9.54) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:27 am

TIL

Instil Bio (NASDAQ:TIL) reported Q2 losses of $(0.14) per share, beating the analyst consensus estimate of $(0.16) by 12.5%. This represents a 69.57% increase over losses from the same period last year. The company also confirmed its prior guidance of cash runway beyond 2026, with a current cash balance of $202.9M.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:27 am

AMPS

Altus Power has reaffirmed its FY23 adjusted EBITDA guidance of $97M-$103M. The company also expects its 2023 adjusted EBITDA margin to be in the mid-to-high fifty percent range.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:23 am

TRVN

Trevena (NASDAQ:TRVN) reported Q2 losses of $(0.69) per share, a 69.33% increase over losses of $(2.25) per share from the same period last year. The company reported $3.02 million in sales this quarter. Cash and cash equivalents were $28.1 million as of June 30, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:23 am

INTS

Intensity Therapeutics reported Q2 losses of $(0.79) per share, missing the analyst consensus estimate of $(0.40) by 97.5 percent.

Portfolio Pulse from vijay@benzinga.com

August 14, 2023 | 11:20 am

ERJ

Embraer (NYSE:ERJ) reported Q2 earnings of $0.32 per share, beating the analyst consensus estimate of $0.12 by 163.33%. The company also reported quarterly sales of $1.29 billion, surpassing the analyst consensus estimate of $1.16 billion by 11.19%. Both earnings and sales have increased compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:18 am

GRCL

Gracell Biotechnologies reported Q2 losses of $(0.01) per share, beating the analyst consensus estimate of $(0.37) by 98.38 percent. This is a 98 percent increase over losses of $(0.30) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:16 am

ONCY

Oncolytics Biotech (NASDAQ:ONCY) reported Q2 losses of $(0.09) per share, meeting analyst consensus. This is a 28.57% decrease from the same period last year. The company reported $24.4 million in cash, cash equivalents, and marketable securities as of June 30, 2023, and closed a $15 million public offering on August 8, 2023. Pro forma cash and equivalents would be approximately $42.7 million.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:14 am

RVLP

RVL Pharmaceuticals (NASDAQ:RVLP) reported Q2 adjusted EPS of $(0.10), beating the estimate of $(0.13) by 23.08%. However, the company's sales of $8.26M missed the estimate of $10.38M by 20.44%. This represents a 28.57% increase in losses and a 2.25% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 11:12 am